Scenario valuation
Scenario valuation of the shares in Auxesis Pharma Holding AB prior to the launch of the company’s analgesic product ASA.P is now available. One-Pager Scenario valuation
Uncategorized
Notice of meeting to the Annual General Meeting
The shareholders in 559195-6486 Auxesis Pharma Holding AB, is hereby convened to the Annual General Meeting on June 10, 2022 at 15.00 in the conference room, Ramberg Law, Jakobsbergsgatan 13, Stockholm To read the notice, please log in to the Investor Hub page with your code.
New Board Members
Welcome as Board Members – Charlotta Larsson and Rune Nordström. Thank you to all shareholders for a great meeting and big thanks to Lars Larsson for all help with implementation of the general meeting.
Exclusive Licensing Agreement
Auxesis Pharma Holding AB has signed a license agreement with Pharma America Corp. in Florida, for a powerful introduction to the entire Americas. The ASA.P® product line, that is the first range of products for market introduction, targets the entire global topical pain relief market and other segments. Auxesis Pharma plans to work worldwide with …
SME status/EMA
En beviljad SME status från EMA betyder att bolaget får lättare tillgång till regulatorisk, finansiell och administrativ assistans från EMA inom utveckling av företagets produkter under alla steg. SME statusen kan förlängas med ett år åt gången så fort uppgifter om bolagets resursflöde för föregående verksamhetsår har rapporterats till EMA. ”Det är viktigt för oss …